Semaglutide Slows Breast Cancer Growth by Boosting Anti-Tumor Immune Response in Mice | Research

The takeaway

Semaglutide decelerated breast cancer growth in mice not through direct tumor cell killing but by enhancing the adaptive immune response — increasing dendritic cell maturation, reducing regulatory T cells, and boosting cytotoxic CD8+ T cell activity.

Immune-mediated, not direct
Semaglutide slowed breast cancer growth not by directly killing cancer cells but by enhancing the immune system's ability to recognize and attack tumors — a mechanism with major implications for cancer prevention

What the researchers found

Semaglutide decelerated tumor appearance and growth in 4T1 breast cancer mice. No direct cytotoxic effect in vitro and no angiogenic effect. NK cell depletion did not affect tumor growth in treated mice. Semaglutide increased CD11c+ dendritic cell accumulation and maturation, decreased FoxP3+ regulatory T cells (in spleen and tumor), increased tumor-infiltrating T cells with anti-tumor phenotype, and enhanced CD8+ T cell cytotoxic capacity.

Why it matters

The finding that a widely-used GLP-1 drug enhances anti-tumor immunity is remarkable and has immediate clinical implications. With millions of patients taking semaglutide for diabetes and obesity, understanding its effects on cancer risk and progression is critical. This study suggests semaglutide may have cancer-protective effects through immunomodulation.

The numbers in context

BALB/c mice with 4T1 breast cancer were treated intraperitoneally with semaglutide. The drug slowed both tumor appearance and growth.

How the study worked

In vivo mouse study: 4T1 breast cancer cells implanted in BALB/c mice, treated with intraperitoneal semaglutide. In vitro cytotoxicity and angiogenesis assays. NK cell depletion experiments. Flow cytometry analysis of dendritic cells, regulatory T cells, and tumor-infiltrating T cells in spleen and primary tumor. In vitro CD8+ T cell cytotoxicity assays.

Who was studied

BALB/c mice with 4T1 breast cancer tumors

What this study cannot tell us

Mouse breast cancer model (4T1) may not fully represent human breast cancer biology or immune responses. Intraperitoneal administration differs from standard subcutaneous dosing. The study didn't assess whether semaglutide's effects depend on weight loss or metabolic changes. Single tumor model — effects may vary across cancer types. No human data on anti-tumor immune effects of semaglutide.

How to read the evidence

Preliminary evidence from a well-designed animal study with mechanistic depth (ruling out direct cytotoxicity and NK dependence, identifying T cell-mediated mechanism). Requires human validation.

When this study was published

Published in 2024, contributing to the rapidly growing literature on non-metabolic effects of GLP-1 receptor agonists.

The bigger picture

Epidemiological studies have hinted that GLP-1 RA users may have lower cancer incidence. This study provides a biological mechanism — semaglutide enhances anti-tumor immunity rather than directly attacking cancer cells. If confirmed in humans, this could mean that the millions of people taking semaglutide for metabolic conditions are also receiving cancer-protective immune benefits.

Questions still open

Do semaglutide's anti-tumor immune effects occur at the doses used clinically for diabetes and obesity?
Could semaglutide enhance the effectiveness of existing immunotherapy drugs like checkpoint inhibitors?

Common questions

Does taking semaglutide for weight loss also protect against cancer?

This mouse study suggests it might — semaglutide enhanced immune surveillance against cancer. Epidemiological data in humans also hint at lower cancer rates in GLP-1 RA users. However, this hasn't been proven in clinical trials, and the mouse doses and administration route differ from human use. It's a promising finding that needs human confirmation.

How does semaglutide help the immune system fight cancer?

Semaglutide appears to 'train' the immune system to better recognize cancer: it increases dendritic cells (which present cancer signals to T cells), reduces regulatory T cells (which normally suppress immune responses), and boosts the cancer-killing ability of CD8+ T cells. Think of it as removing the brakes while pressing the gas pedal on anti-tumor immunity.

Read the original research

Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 181, 117668

View on PubMed ↗Publisher’s paper ↗

Citation

Stanisavljevic, Isidora; Pavlovic, Sladjana; Simovic Markovic, Bojana; Jurisevic, Milena; Krajnovic, Tamara; Mijatovic, Sanja; Spasojevic, Marija; Mitrovic, Slobodanka; Corovic, Irfan; Jovanovic, Ivan. (2024). Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 181, 117668. https://doi.org/10.1016/j.biopha.2024.117668